HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
about
Current and emerging strategies for the prevention of graft-versus-host diseaseMilestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current DevelopmentsRole of HLA in Hematopoietic Stem Cell Transplantation.A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationPharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.T cell depletion in paediatric stem cell transplantation.Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.The current role of T cell depletion in paediatric stem cell transplantation.Allogeneic transplantation in the UK: an aggregation of marginal gains?The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.No effect of HLA-C mismatch after allogeneic hematopoietic stem cell transplantation with unrelated donors and T-cell depletion in patients with hematological malignancies.Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.Alemtuzumab in allogeneic hematopoetic stem cell transplantation.In a 12-allele analysis HLA-DPB1 matching is associated with improved OS in leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted PBSCT from unrelated donors.Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission.Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia.
P2860
Q27016541-0BB1E104-6F6F-4E83-AEDB-4F564F170248Q28067102-AA60E449-B4A8-4269-8F37-F4484F05AFF1Q36307305-F7CD9535-0B6B-439B-9E7C-8A05FDD7D951Q36532550-B279D253-E68E-44ED-94D1-1033010FDF5CQ36891433-7FABBB02-9D16-4222-A0E9-11E36C02ED2DQ36980277-850EC531-2BEC-439A-BD65-CAEA58AD1DA7Q38023947-C6768A06-BDA6-4D62-B1AA-6077A31AC934Q38066586-304F4C0C-5D99-4D03-A309-67A19160C357Q38097916-482812C6-CE24-47F2-94FE-FCCC41F62C3FQ38098957-8CF14D99-B56A-4F8D-8170-39C3760A2B52Q38110308-2B00A1FB-6D9F-40FE-817F-B9D89D4EF1A4Q38124363-BF352582-54E4-4131-85FD-D5846CB1E27DQ38547042-32AF12F3-B5B4-4CB1-9BBA-96CE9798BDC9Q38782925-9A8DBE13-C461-4C74-A131-A4BF9B19BAE1Q38797660-A3811B6B-AC7B-405C-983A-FE7EBFB07320Q42149544-452451F6-DA5C-4218-84BC-9FDF5FEFB7D6Q44571503-386B1020-8BAE-406B-ACD0-979D9DCE7E99Q44919804-919D2A20-C743-4A08-A24F-7EF61DDB03F1Q46639944-AD49B946-94C1-4C59-A0F2-2D3D5A2CEF79Q51017254-992B4115-86FE-4DCA-866F-ADEBF08024C3
P2860
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
HLA-mismatched unrelated donor ...... educed-intensity conditioning.
@en
HLA-mismatched unrelated donor ...... educed-intensity conditioning.
@nl
type
label
HLA-mismatched unrelated donor ...... educed-intensity conditioning.
@en
HLA-mismatched unrelated donor ...... educed-intensity conditioning.
@nl
prefLabel
HLA-mismatched unrelated donor ...... educed-intensity conditioning.
@en
HLA-mismatched unrelated donor ...... educed-intensity conditioning.
@nl
P2093
P50
P1433
P1476
HLA-mismatched unrelated donor ...... educed-intensity conditioning.
@en
P2093
Adele K Fielding
David C Linch
Guillermo Orti
Karl S Peggs
Kirsty J Thomson
Panagiotis D Kottaridis
Rachael Hough
Sajir Mohamedbhai
Shari Denovan
Stephen Mackinnon
P304
P356
10.1182/BLOOD-2010-01-265413
P407
P577
2010-04-06T00:00:00Z